
- 45 year-old male patient seen at the clinic (Medicine).
- Workplace stress (financial analyst); occasionally goes jogging.
- Two-year duration of T2DM. No previous cardiovascular events. Coexisting mild intermittent asthma.
- BMI: 32.
- On diet + metformin, HbA1C = 7.8%.
- FPG in the morning ≈ 120-130 mg/dl.
- Next step in his medical management?

# Physiology of Normoglycemia



#### **Tools to Control G Levels**

Increase the effect of available insulin

Diet +/- weight loss

**Activity** 

Metformin (liver)

TZDs (fat, muscle, liver)

Increase the supply of insulin (to increase effect)

Sulfonylureas

Glinides

Insulin

Incretins (GLP-1, DPP4-I)

 Reduce the need for insulin supply (improve the match between insulin supply & effect)

AGIs (acarbose)

SGLT2 inhibitors

Incretins (GLP-1, DPP4-I) Pramlintide

#### **Tools to Lower G Levels**

Insulin: Long acting: *glargine, detemir, degludec, NPH* 

Medium: regular

Rapid: lispro, aspart, glulisine

• Sulfonylurea: glyburide\*, gliclazide, glimepiride, glipizide

Glinide: repaglinide, nateglinide

Biguanide: metformin

• TZD: pioglitazone, rosiglitazone


SGLT2i: canagliflozin, dapagliflozin, empagliflozin

• GLP -1 analog: exenatide, liraglutide, lixisenatide

• DPP4-I: sitagliptin, vildagliptin, saxagliptin

Alpha Glucosidase Inhibitor: acarbose, miglitol

# **Tools to Lower G Levels**



- 45 year-old male patient seen at the clinic (Medicine).
- Workplace stress (financial analyst); occasionally goes jogging.
- Two-year duration of T2DM. No previous cardiovascular events. Coexisting mild intermittent asthma.
- BMI: 32.
- On diet + metformin, HbA1C = 7.8%.
- FPG in the morning ≈ 120-130 mg/dl.
- Next step in his medical management?

- 60 year-old male patient, admitted for NSTEMI, treated with angioplasty.
- Roughly, 10-yr duration of T2DM. Hypertension. Hypercholesterolemia. Intermittent claudication.
- BMI: 31.
- eGFR = 70 ml/min/1.73m<sup>2</sup>.
- HbA1C = 8.1%.
- Treatment before current admission: metformin, 850 mg/12 h plus sustained-release gliclazide, 90 mg/day.
- Any changes in treatment before/at discharge?

#### **How to start insulin it: INSIGHT Trial**

In people with type 2 diabetes who are treated with lifestyle alone, 1 agent or sub-maximal doses of 2 oral agents by specialists or generalists & can easily be managed without insulin....

... does the addition & titration of basal insulin to a  $FPG \le 5.5 \text{ mmol/L}$  (100 mg/dL) safely achieve an  $A1c \le 6.5\%$  faster & more frequently than increasing or adding oral agents?

#### **Trial Design**

Lifestyle alone

1 oral agent, (SU, Metformin Repaglinide)

2 oral agents where at least is at ≤ half max. dose

Current Rx + Insulin Glargine
Titrated to FPG < 5.5 (100)

→ RAND

Oral agent mono-Rx (SU, metformin, repaglinide) OR
Dose/add a 2<sup>nd</sup> oral agent OR
Dose of 2 agents to max OR
Add a 3rd agent

-2 Wks

Wk 0 (başeline)

Wk 24 (end)


Screening phase


Treatment phase

# **Baseline Characteristics**


	Total	Insulin	OADs
	405	206	199
Expert (%)	145 (35.8)	75 (36.4)	70 (35.2)
Family MD (%)	260 (64.2)	131 (63.6)	129 (64.8)
Age (yrs)	56.5 (9.8)	56.3 (9.4)	56.8 (10.1)
DM Duration (yrs)	7.9 (6.0)	7.6 (5.4)	8.2 (6.5)
BMI (kg/m²)	31.3 (4.5)	31.1 (4.4)	31.5 (4.6)
A1c (%)	8.6 (1.0)	8.6 (1.0)	8.5 (1.0)
Drug Naïve (%)	68 (16.8)	38 (18.4)	30 (15.1)
Metformin or SU (%)	165 (40.7)	81 (39.3)	84 (42.2)
Metformin & SU (%) HCG 2014	172 (42.5)	87 (42.2)	85 (42.7)

# Achieved A1c (95% CI)






# Hypoglycemia & Weight



(Adj. baseline, site stratum)	Glargine	OAD	Diff. (95% CI)
Final – Initial Waist	1.23	-0.74	1.97 (0.96, 2.98)
Final – Initial BMI	0.72	0.06	0.65 (0.39, 0.92)
Final – Initial Weight	2.11	0.16	1.94 (1.16, 2.73)

# Other Endpoints



- 60 year-old male patient, admitted for NSTEMI, treated with angioplasty.
- Roughly, 10-yr duration of T2DM. Hypertension. Hypercholesterolemia. Intermittent claudication.
- BMI: 31.
- eGFR = 70 ml/min/1.73m<sup>2</sup>.
- HbA1C = 8.1%.
- Treatment before current admission: metformin, 850 mg/12 h plus sustained-release gliclazide, 90 mg/day.
- Any changes in treatment before/at discharge?

- 38 year-old man; formerly unknown diabetes; admits having recently experienced polyuria and polydipsia.
- Admitted to the ICU for pneumonia and shock, needing steroids and mechanical ventilation.
- BMI at admission: 40 (weight: 130 kg). At discharge: 36.
- HbA1c = 9%.
- At the Medicine ward he is treated with metformin 850 mg/12h plus basal-boluses insulin.
- After spending 19 days in the hospital, he is close to be discharged in good condition. Gone off steroids now.
- Basal glargine dose has been gradually reduced to 14 IU at night, needing additional glulisine 5 IU for lunch.
- Would you keep this treatment at discharge?

# **Potential Approaches**

- Consider the big picture!!!
- What type of diabetes does he have???
- Intensive medical therapy
  - Lifestyle
  - Drugs
- Metabolic surgery

# Features of Basal Insulin Therapy

The G level tells you when the dose is right

There is no maximum or minimum dose

Easily titrated & virtually painless

No contraindication & no true drug interactions

Easy-to-use insulin preparations & delivery devices
Often only need 1 dose/day

Medicine has more experience with insulin therapy than almost any other agent (i.e. 91 years)

- 75 year-old female patient seen at the clinic.
- 25 year-duration T2DM. Long-standing stable angina due to small vessels obstruction, not amenable to PCI. LVEF: 55%.
- CKD with confirmed microalbuminuria (180 mg/g) and eGFR = 58 ml/min/1.73m<sup>2</sup>.
- Recent weight gain; BMI: 30.5.
- HbA1C = 8%.
- Current treatment: metformin 850 mg/12h plus linagliptin 5 mg/day.
- Next step?